1. Home
  2. PELI vs CSBR Comparison

PELI vs CSBR Comparison

Compare PELI & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PELI
  • CSBR
  • Stock Information
  • Founded
  • PELI 2024
  • CSBR 1985
  • Country
  • PELI United States
  • CSBR United States
  • Employees
  • PELI N/A
  • CSBR N/A
  • Industry
  • PELI
  • CSBR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PELI
  • CSBR Health Care
  • Exchange
  • PELI NYSE
  • CSBR Nasdaq
  • Market Cap
  • PELI 120.1M
  • CSBR 111.4M
  • IPO Year
  • PELI 2025
  • CSBR 1986
  • Fundamental
  • Price
  • PELI $10.00
  • CSBR $8.33
  • Analyst Decision
  • PELI
  • CSBR Strong Buy
  • Analyst Count
  • PELI 0
  • CSBR 1
  • Target Price
  • PELI N/A
  • CSBR $12.00
  • AVG Volume (30 Days)
  • PELI 45.5K
  • CSBR 39.6K
  • Earning Date
  • PELI 01-01-0001
  • CSBR 09-10-2025
  • Dividend Yield
  • PELI N/A
  • CSBR N/A
  • EPS Growth
  • PELI N/A
  • CSBR N/A
  • EPS
  • PELI N/A
  • CSBR 0.46
  • Revenue
  • PELI N/A
  • CSBR $58,591,000.00
  • Revenue This Year
  • PELI N/A
  • CSBR $15.11
  • Revenue Next Year
  • PELI N/A
  • CSBR $7.80
  • P/E Ratio
  • PELI N/A
  • CSBR $17.71
  • Revenue Growth
  • PELI N/A
  • CSBR 19.03
  • 52 Week Low
  • PELI $10.01
  • CSBR $3.60
  • 52 Week High
  • PELI $10.43
  • CSBR $11.99
  • Technical
  • Relative Strength Index (RSI)
  • PELI N/A
  • CSBR 64.00
  • Support Level
  • PELI N/A
  • CSBR $7.16
  • Resistance Level
  • PELI N/A
  • CSBR $9.63
  • Average True Range (ATR)
  • PELI 0.00
  • CSBR 0.64
  • MACD
  • PELI 0.00
  • CSBR 0.11
  • Stochastic Oscillator
  • PELI 0.00
  • CSBR 69.06

About PELI PELICAN ACQUISITION CORPORATION

Pelican Acquisition Corp is a blank check company.

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Share on Social Networks: